Two dosing levels of ranibizumab show good effects in eyes with DME

Two dosing levels of ranibizumab improved visual acuity and decreased central foveal thickness in patients with clinically significant diabetic macular edema, a study found.The prospective study included 46 eyes of 46 patients with DME secondary to diabetic retinopathy. Patients were randomized 1:1 to receive intravitreal injections of 0.5 mg or 1 mg Lucentis (ranibizumab, Genentech) once monthly for 3 months and subsequently once every other month as needed.